Dynamic quotes: Off
|
Company Description (as filed with the SEC)
In this Annual Report, we sometimes refer to CytRx Corporation as “CytRx,” to our former subsidiary, RXi Pharmaceuticals Corporation (now known as Galena Biopharma, Inc.), as “RXi,” and to Innovive Pharmaceuticals, Inc., which we acquired in September 2008, as “Innovive.” References in this Annual Report to the “company,” “we,” “us” or “our” refer to CytRx, unless otherwise indicated. COMPANY OVERVIEW We are a biopharmaceutical research and development company specializing in oncology. Our oncology pipeline includes two programs in clinical development for cancer indications: aldoxorubicin (formerly known as INNO-206) and tamibarotene. ... More ...
Analyst Info |
|
| Annual EPS Est: | $ |
| Quarterly EPS Est: | |
| PEG Ratio: | N/A |
|
Mean Recommendation: View Summary / View All |
1 |
Data is provided by Zacks Investment Research
